What’s Ahead for Aptose Biosciences Incorporated (NASDAQ:APTO) After Less Shorted Shares?

October 13, 2017 - By Nellie Frank

 What’s Ahead for Aptose Biosciences Incorporated (NASDAQ:APTO) After Less Shorted Shares?

The stock of Aptose Biosciences Incorporated (NASDAQ:APTO) registered a decrease of 7.06% in short interest. APTO’s total short interest was 947,600 shares in October as published by FINRA. Its down 7.06% from 1.02 million shares, reported previously. With 148,400 shares average volume, it will take short sellers 6 days to cover their APTO’s short positions. The short interest to Aptose Biosciences Incorporated’s float is 6.02%.

The stock decreased 0.71% or $0.01 on October 13, reaching $1.39. About 127,953 shares traded. Aptose Biosciences Inc (NASDAQ:APTO) has declined 60.81% since October 13, 2016 and is downtrending. It has underperformed by 77.51% the S&P500.

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company has market cap of $33.06 million. The Firm is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. It currently has negative earnings. The Company’s product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Aptose Biosciences Inc (NASDAQ:APTO) Ratings Coverage

Among 4 analysts covering Aptose Biosciences (NASDAQ:APTO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Aptose Biosciences had 11 analyst reports since August 7, 2015 according to SRatingsIntel. As per Thursday, September 7, the company rating was upgraded by H.C. Wainwright. As per Monday, June 13, the company rating was upgraded by Roth Capital. The firm has “Outperform” rating given on Wednesday, November 16 by RBC Capital Markets. The firm earned “Hold” rating on Thursday, June 8 by H.C. Wainwright. The stock of Aptose Biosciences Inc (NASDAQ:APTO) earned “Neutral” rating by TH Capital on Friday, November 20. The stock of Aptose Biosciences Inc (NASDAQ:APTO) has “Hold” rating given on Wednesday, August 9 by H.C. Wainwright. The rating was upgraded by Zacks to “Hold” on Friday, August 7. The firm has “Neutral” rating given on Friday, November 20 by Roth Capital. The stock of Aptose Biosciences Inc (NASDAQ:APTO) earned “Outperform” rating by RBC Capital Markets on Wednesday, November 11.

More notable recent Aptose Biosciences Inc (NASDAQ:APTO) news were published by: Globenewswire.com which released: “Aptose Reports Results for the Second Quarter Ended June 30, 2017” on August 08, 2017, also Globenewswire.com with their article: “Aptose Biosciences Announces Results of Annual Meeting of Shareholders” published on June 06, 2017, Seekingalpha.com published: “Aptose Biosciences’ (APTO) CEO William Rice on Q2 2017 Results – Earnings Call …” on August 12, 2017. More interesting news about Aptose Biosciences Inc (NASDAQ:APTO) were released by: Seekingalpha.com and their article: “Aptose Remains In Limbo” published on November 04, 2016 as well as Globenewswire.com‘s news article titled: “Aptose Biosciences Provides Update on APTO-253 Development” with publication date: December 29, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.